Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Exploring the Gig Economy: Illustrations from Consultants - 2Understanding Preschool Projects: Cultivating Abilities and Advancement
- 3The moon and sun figure big in the new year's lineup of cosmic wonders
- 4Israeli archaeologists launch project to trace origins of ancient pottery
- 5Bavarian leader questions Germany's Eurovision participation
- Meet the Stars of the Feline World: Well known Pet Feline Varieties
- Most normal matter in the universe isn't found in planets, stars or galaxies – an astronomer explains where it's distributed
- A company is trying to unlock a key to aging, in a long-overlooked body part
- 5 Critical Rules For Business Regulation Chiefs
- 6 Financial plan 3D Printers with the Best Worth
- The Development of Shipping: Controlling Towards a More Associated Future
- Unfathomable and Entertaining Legal disputes That Surprise everyone
- Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- Wedding trip Objections in Europe
